Excitotoxic insult due to ibogaine leads to delayed induction of neuronal NOS in Purkinje cells.
E O'Hearn, P Zhang, M E Molliver
Neuroreport August 21, 1995 DOI: 10.1097/00001756-199508000-00006 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Purkinje cells in the brain |
| Intervention | Ibogaine |
| Topics | Ibogaine |
| Citations | 77 |
| Key findings | Ibogaine induces delayed expression of nNOS in Purkinje cells adjacent to degenerated ones, suggesting NO may be involved in recovery or delayed cell death after excitotoxic injury. |
Abstract
Ibogaine causes degeneration of Purkinje cells (PKCs), presumably via activation of neurons in the inferior olive leading to release of glutamate at climbing fiber terminals. Following ibogaine administration, some Purkinje cells express NADPH-diaphorase and neuronal NOS (nNOS), neither of which is present normally in these cells. The induction of NOS is delayed in onset, dose-related, and detected in neurons adjacent to degenerated PKCs. The results demonstrate that nNOS induction can follow excitotoxic neuronal injury or perturbation. However, NO is unlikely to participate in the initial phase of PKC damage. Both the late induction of nNOS and the spatial relationship between damaged and nNOS-expressing PKCs are consistent with a role for NO in either neuronal recovery or delayed cell death following excitotoxic injury.
Comparable studies
Other experimental studies on ibogaine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. In vitro (SERT) | 2007 | Laboratory study | |
| Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. | 1992 | Laboratory study | |
| The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. | 2012 | Experimental study | |
| Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. | 1995 | Experimental study | |
| Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity. | 1995 | Laboratory study |
Citations in the library
Cited by 5
- The Olivocerebellar Projection Mediates Ibogaine-Induced Degeneration of Purkinje Cells: A Model of Indirect, Trans-Synaptic Excitotoxicity Journal of Neuroscience November 15, 1997
- Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine. Neuroscience 2004
- Ibogaine alters synaptosomal and glial glutamate release and uptake. Neuroreport February 12, 2001
- Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging. Annals of the New York Academy of Sciences May 30, 1997
- Ibogaine: Ibogaine therapy as a method of care treatment for opioid dependence Psychedelics as Psychiatric Medications March 1, 2023